ClinicalTrials.gg
Drug

MYK-461 clinical trials

Also written Mavacamten, MYK-461 and BMS-986427.

studies test it
24
open now
3
in phase 3
7
first study started
2014

How each study uses MYK-461 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the MYK-461 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
28 Apr 2022 · CAMZYOS · NDA 214998 (FDA, Drugs@FDA)
European Union
26 Jun 2023 · Camzyos · EMEA/H/C/005457 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

MYK-461
13
BMS-986427
5
BMS-986327
1

Other names

Mavacamten
19

Studies by the year they started

24 studies that test it; most in 2022 (5)

Studies that test MYK-461, by start year
YearStudies
20141
20152
20161
20184
20201
20212
20225
20231
20242
20252
20263

By phase

A phase 1/2 study counts in both.

Phase 1
7
Phase 2
5
Phase 3
7
Phase 4
4
No phase
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 20 · Other 4

Bristol-Myers Squibb (12) · MyoKardia, Inc. (6) · LianBio LLC (2) · Xu Liu (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Second Affiliated Hospital of Nanchang University (1) · University of Manchester (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test MYK-461.

Studies

Open first, then newest update. How each study uses MYK-461 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 24

See all 24 studies that test MYK-461 →

Given beside what is tested · 1 — MYK-461 is usual care or a partner of the new treatment

Codes

What other systems call MYK-461 · ClinicalTrials.gg INT000419

  • MeSH (NLM) C000605992MYK-461Confirmed ClinicalTrials.gov, NLM
  • UNII (FDA) QX45B99R3JMAVACAMTENConfirmed FDA, NLM
  • RxNorm 2600867One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.